8
Phase 2–4 trials
Two RNA-targeted therapies for lipid and Lp(a) lowering
Olezarsen vs pelacarsen: trial pipelines compared
A side-by-side view of the olezarsen and pelacarsen clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 8 phase 2–4 trials for olezarsen and 10 for pelacarsen. Add up to three more drugs to widen the comparison.
olezarsen (8) vs pelacarsen (10)10 active2017–2032
olezarsenpelacarsen
'17
'19
'21
'23
'25
'27
'29
'31
olezarsen
BALANCEP3
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe HypertriglyceridemiaP3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)P3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With VolanesorsenP3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaP2
A Study of Olezarsen Administered Subcutaneously to Participants With Severe HypertriglyceridemiaP3
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaP3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)P3
pelacarsen
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseP2
Lp(a)HORIZONP3
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyP3
OLEP3
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisP2
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDP3
ADD-VANTAGEP3
Pelacarsen Roll-over Extension ProgramP3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)P3
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLP3
Upcoming readouts
9 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
olezarsen (Tryngolza)Lipid & Lp(a) therapies
7
Phase 3 trials
0
Actively recruiting
Mar 2027
Next phase 3 readout
pelacarsenLipid & Lp(a) therapies
10
Phase 2–4 trials
8
Phase 3 trials
4
Actively recruiting
Feb 2028
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across olezarsen and pelacarsen, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Drug | Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|---|
| pelacarsen | NCT06813911 | ADD-VANTAGE: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elev… | Phase 3 | Recruiting | Feb 2028 |
| pelacarsen | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-ter… | Phase 3 | Recruiting | Jan 2030 |
| pelacarsen | NCT06875973 | Pelacarsen Roll-over Extension Program | Phase 3 | Recruiting | Dec 2030 |
| pelacarsen | NCT04023552 | Lp(a)HORIZON: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascula… | Phase 3 | Active, not recruiting | Jun 2026 |
| olezarsen | NCT05681351 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Se… | Phase 3 | Active, not recruiting | Mar 2027 |
| olezarsen | NCT05185843 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial … | Phase 3 | Active, not recruiting | Jun 2027 |
| olezarsen | NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomi… | Phase 3 | Active, not recruiting | Feb 2028 |
| pelacarsen | NCT05900141 | OLE: An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen … | Phase 3 | Active, not recruiting | Aug 2028 |
| pelacarsen | NCT07625306 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent… | Phase 3 | Not yet recruiting | Dec 2028 |
| olezarsen | NCT04568434 | BALANCE: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familia… | Phase 3 | Completed | Jul 2023 |
| olezarsen | NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic… | Phase 3 | Completed | Aug 2024 |
| olezarsen | NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia | Phase 3 | Completed | Oct 2024 |
| olezarsen | NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemi… | Phase 3 | Completed | Dec 2024 |
| pelacarsen | NCT05305664 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on … | Phase 3 | Completed | Jan 2025 |
| pelacarsen | NCT06267560 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participan… | Phase 3 | Completed | Mar 2026 |
| pelacarsen | NCT05646381 | A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on … | Phase 2 | Recruiting | Mar 2030 |
Individual pipelines and other comparisons
FAQ
- How do the olezarsen and pelacarsen clinical pipelines compare?
- ClinicalTrials.gov currently lists 8 phase 2–4 trials for olezarsen and 10 for pelacarsen. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.